Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

The role of vasoactive intestinal peptide (VIP) in megakaryocyte proliferation.

Nam C, Case AJ, Hostager BS, O'Dorisio MS.

J Mol Neurosci. 2009 Feb;37(2):160-7. doi: 10.1007/s12031-008-9119-x.

PMID:
18663606
2.

Suppression of tumorigenicity in neuroblastoma cells by upregulation of human vasoactive intestinal peptide receptor type 1.

Balster DA, O'Dorisio MS, Albers AR, Park SK, Qualman SJ.

Regul Pept. 2002 Nov 15;109(1-3):155-65.

PMID:
12409228
3.
4.

PACAP and its receptor VPAC1 regulate megakaryocyte maturation: therapeutic implications.

Freson K, Peeters K, De Vos R, Wittevrongel C, Thys C, Hoylaerts MF, Vermylen J, Van Geet C.

Blood. 2008 Feb 15;111(4):1885-93.

5.
6.

Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts.

Juarranz Y, Gutiérrez-Cañas I, Santiago B, Carrión M, Pablos JL, Gomariz RP.

Arthritis Rheum. 2008 Apr;58(4):1086-95. doi: 10.1002/art.23403.

7.
8.

Vasoactive intestinal peptide (VIP) inhibits the proliferation of bone marrow progenitors through the VPAC1 receptor.

Rameshwar P, Gascon P, Oh HS, Denny TN, Zhu G, Ganea D.

Exp Hematol. 2002 Sep;30(9):1001-9.

PMID:
12225791
9.

Down-regulation of vasoactive intestinal peptide and altered expression of its receptors in rat diabetic cardiomyopathy.

Dvoráková MC, Pfeil U, Kuncová J, Svíglerová J, Galvis G, Krasteva G, König P, Grau V, Slavíková J, Kummer W.

Cell Tissue Res. 2006 Mar;323(3):383-93.

PMID:
16344947
10.
11.

Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells.

Delgado M, Robledo G, Rueda B, Varela N, O'Valle F, Hernandez-Cortes P, Caro M, Orozco G, Gonzalez-Rey E, Martin J.

Arthritis Rheum. 2008 Apr;58(4):1010-9. doi: 10.1002/art.23482.

12.

Effect of vasoactive intestinal peptide on gastric adenocarcinoma.

Li GH, Qian W, Song GQ, Hou XH.

J Gastroenterol Hepatol. 2007 Aug;22(8):1328-35.

PMID:
17559364
13.

Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue.

García-Fernández MO, Collado B, Bodega G, Cortés J, Ruíz-Villaespesa A, Carmena MJ, Prieto JC.

Gynecol Endocrinol. 2005 Jun;20(6):327-33.

PMID:
16019382
14.

A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.

Summers MA, O'Dorisio MS, Cox MO, Lara-Marquez M, Goetzl EJ.

J Pharmacol Exp Ther. 2003 Aug;306(2):638-45.

15.

Expression and fine mapping of murine vasoactive intestinal peptide receptor 1.

Karacay B, O'Dorisio MS, Kasow K, Hollenback C, Krahe R.

J Mol Neurosci. 2001 Dec;17(3):311-24.

PMID:
11859927
16.

Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog.

Collado B, Carmena MJ, Sánchez-Chapado M, Ruíz-Villaespesa A, Bajo AM, Fernández-Martínez AB, Varga JL, Schally AV, Prieto JC.

Int J Oncol. 2005 Jun;26(6):1629-35.

PMID:
15870879
18.

Regulation of vasoactive intestinal peptide receptor expression in developing nervous systems.

Karacay B, O'Dorisio MS, Summers M, Bruce J.

Ann N Y Acad Sci. 2000;921:165-74.

PMID:
11193820
19.

VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production.

Kojima M, Ito T, Oono T, Hisano T, Igarashi H, Arita Y, Kawabe K, Coy DH, Jensen RT, Nawata H.

Pancreas. 2005 Jan;30(1):62-70.

PMID:
15632701
20.

Vasoactive intestinal peptide and its receptors in human ovarian cortical follicles.

Gabbay-Benziv R, Ao A, Fisch B, Zhang L, Oron G, Kessler-Icekson G, Ben-Haroush A, Krissi H, Abir R.

PLoS One. 2012;7(5):e37015. doi: 10.1371/journal.pone.0037015.

Supplemental Content

Support Center